Literature DB >> 2778479

Spondylectomy for malignant tumors of the spine.

N Sundaresan1, G V DiGiacinto, G Krol, J E Hughes.   

Abstract

Spondylectomy is the complete surgical removal of all parts of one or more vertebrae above the sacrum. We report our initial experience with spondylectomy in eight patients with malignant tumors of the spine operated on over a 7-year period (1980 to 1986). Four patients had primary neoplasms of the spine, and four others had solitary metastases to the vertebrae. Following surgery, five patients underwent radiation therapy (RT) and chemotherapy depending on histology of the tumor. Radiographic confirmation of tumor resection was obtained on all patients. Pain relief was noted in all patients, and six patients with preoperative neurological deficits improved. There was no surgical mortality, and one patient developed wound dehiscence following surgery. Six of the eight patients are alive with a median follow-up of 36 months, and local control was achieved in six of the eight patients. These preliminary data suggest that malignant tumors of the spine can be completely resected using a staged approach. In potentially responsive tumors, systemic chemotherapy is recommended between the two operations to reduce the risk of systemic dissemination.

Entities:  

Mesh:

Year:  1989        PMID: 2778479     DOI: 10.1200/JCO.1989.7.10.1485

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  11 in total

Review 1.  Clinical effectiveness of Enneking appropriate versus Enneking inappropriate procedure in patients with primary osteosarcoma of the spine: a systematic review with meta-analysis.

Authors:  Bruno Pombo; Ana Cristina Ferreira; Pedro Cardoso; António Oliveira
Journal:  Eur Spine J       Date:  2019-08-13       Impact factor: 3.134

2.  Surgeon's perception of margins in spinal en bloc resection surgeries: how reliable is it?

Authors:  Ran Lador; Alessandro Gasbarrini; Marco Gambarotti; Stefano Bandiera; Riccardo Ghermandi; Stefano Boriani
Journal:  Eur Spine J       Date:  2017-02-06       Impact factor: 3.134

3.  Incidence and outcome of bone metastatic disease at University Malaya Medical Centre.

Authors:  Vivek Ajit Singh; Amber Haseeb; Alla Allden H Ali Alkubaisi
Journal:  Singapore Med J       Date:  2014-10       Impact factor: 1.858

4.  The results of surgery on primary malignant tumors of the spine.

Authors:  H Takaishi; H Yabe; Y Fujimura; N Suzuki; Y Toyama
Journal:  Arch Orthop Trauma Surg       Date:  1996       Impact factor: 3.067

Review 5.  Thoracolumbar corpectomy/spondylectomy for spinal metastasis: a pooled analysis comparing the outcome of seven different surgical approaches.

Authors:  Alexander Spiessberger; Varun Arvind; Basil Gruter; Samuel K Cho
Journal:  Eur Spine J       Date:  2019-10-22       Impact factor: 3.134

6.  Total en bloc spondylectomy for solitary spinal metastases.

Authors:  K Tomita; N Kawahara; H Baba; H Tsuchiya; S Nagata; Y Toribatake
Journal:  Int Orthop       Date:  1994-10       Impact factor: 3.075

Review 7.  Tumors of the osseous spine.

Authors:  Narayan Sundaresan; Stephano Boriani; Allen Rothman; Robert Holtzman
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

8.  Predictors for surgical complications of en bloc resections in the spine: review of 220 cases treated by the same team.

Authors:  Stefano Boriani; Alessandro Gasbarrini; Stefano Bandiera; Riccardo Ghermandi; Ran Lador
Journal:  Eur Spine J       Date:  2016-03-14       Impact factor: 3.134

9.  [Surgical therapy of pelvis and spine in primary malignant bone tumors].

Authors:  R Windhager; H Welkerling; N Kastner; P Krepler
Journal:  Orthopade       Date:  2003-11       Impact factor: 1.087

10.  Osteosarcoma of the spine: surgical treatment and outcomes.

Authors:  Dapeng Feng; Xinghai Yang; Tielong Liu; Jianru Xiao; Zhipeng Wu; Quan Huang; Junming Ma; Wending Huang; Wei Zheng; Zhiming Cui; Huazi Xu; Yong Teng
Journal:  World J Surg Oncol       Date:  2013-04-18       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.